Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults

NCT03443427 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03443427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03443427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 20, 2018
Completion date
September 23, 2020
Enrollment
200 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory disorders